Biotechnology Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada – Scilex Holding (NASDAQ:SCLX) Read more
Biotechnology Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose Technology Entitled “Low Glycemic Sugar Composition.” – DSS (AMEX:DSS) Read more